Gossypol Interferes With Both Type I and Type Ii Topoisomerase Activities Without Generating Strand Breaks
| dc.contributor.author | Şenarısoy, Müge | |
| dc.contributor.author | Cantürk, Pakize | |
| dc.contributor.author | Zencir, Sevil | |
| dc.contributor.author | Baran, Yusuf | |
| dc.contributor.author | Topçu, Zeki | |
| dc.coverage.doi | 10.1007/s12013-012-9468-5 | |
| dc.date.accessioned | 2017-04-19T11:38:34Z | |
| dc.date.available | 2017-04-19T11:38:34Z | |
| dc.date.issued | 2013 | |
| dc.description.abstract | A considerable number of agents with chemotherapeutic potentials reported over the past years were shown to interfere with the reactions of DNA topoisomerases, the essential enzymes that regulate conformational changes in DNA topology. Gossypol, a naturally occurring bioactive phytochemical is a chemopreventive agent against various types of cancer cell growth with a reported activity on mammalian topoisomerase II. The compounds targeting topoisomerases vary in their mode of action; class I compounds act by stabilizing covalent topoisomerase-DNA complexes resulting in DNA strand breaks while class II compounds interfere with the catalytic function of topoisomerases without generating strand breaks. In this study, we report Gossypol as the interfering agent with type I topoisomerases as well. We also carried out an extensive set of assays to analyze the type of interference manifested by Gossypol on DNA topoisomerases. Our results strongly suggest that Gossypol is a potential class II inhibitor as it blocked DNA topoisomerase reactions with no consequently formed strand breaks. | en_US |
| dc.description.sponsorship | Scientific and Technological Research Council of Turkey (TBAG-108T548) | en_US |
| dc.identifier.citation | Şenarısoy, M., Cantürk, P., Zencir, S., Baran, Y., and Topçu, Z. (2013). Gossypol interferes with both type I and Type II topoisomerase activities without generating strand breaks. Cell Biochemistry and Biophysics, 66(1), 199-204. doi:10.1007/s12013-012-9468-5 | en_US |
| dc.identifier.doi | 10.1007/s12013-012-9468-5 | |
| dc.identifier.doi | 10.1007/s12013-012-9468-5 | en_US |
| dc.identifier.issn | 1085-9195 | |
| dc.identifier.issn | 1559-0283 | |
| dc.identifier.scopus | 2-s2.0-84876183776 | |
| dc.identifier.uri | https://doi.org/10.1007/s12013-012-9468-5 | |
| dc.identifier.uri | https://hdl.handle.net/11147/5350 | |
| dc.language.iso | en | en_US |
| dc.publisher | Humana Press | en_US |
| dc.relation | info:eu-repo/grantAgreement/TUBITAK/TBAG/108T548 | en_US |
| dc.relation.ispartof | Cell Biochemistry and Biophysics | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Anticancer drug research | en_US |
| dc.subject | DNA strand breaks | en_US |
| dc.subject | DNA topoisomerases | en_US |
| dc.subject | Gossypol | en_US |
| dc.subject | Gyrase inhibitor | en_US |
| dc.title | Gossypol Interferes With Both Type I and Type Ii Topoisomerase Activities Without Generating Strand Breaks | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.institutional | Baran, Yusuf | |
| gdc.author.yokid | 119193 | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C4 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Institute of Technology. Molecular Biology and Genetics | en_US |
| gdc.description.endpage | 204 | en_US |
| gdc.description.issue | 1 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q4 | |
| gdc.description.startpage | 199 | en_US |
| gdc.description.volume | 66 | en_US |
| gdc.description.wosquality | Q3 | |
| gdc.identifier.openalex | W2167137679 | |
| gdc.identifier.pmid | 23161103 | |
| gdc.identifier.wos | WOS:000317860900023 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.accesstype | BRONZE | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.downloads | 1 | |
| gdc.oaire.impulse | 4.0 | |
| gdc.oaire.influence | 3.1206573E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | 570 | |
| gdc.oaire.keywords | enzyme assay | |
| gdc.oaire.keywords | Macromolecular Substances | |
| gdc.oaire.keywords | Type I | |
| gdc.oaire.keywords | 610 | |
| gdc.oaire.keywords | Anticancer drug research | |
| gdc.oaire.keywords | chemistry | |
| gdc.oaire.keywords | Type II | |
| gdc.oaire.keywords | macromolecule | |
| gdc.oaire.keywords | plasmid | |
| gdc.oaire.keywords | DNA strand breaks | |
| gdc.oaire.keywords | Enzyme Stability | |
| gdc.oaire.keywords | Animals | |
| gdc.oaire.keywords | Topoisomerase II Inhibitors | |
| gdc.oaire.keywords | DNA topoisomerases | |
| gdc.oaire.keywords | animal | |
| gdc.oaire.keywords | DNA topoisomerase (ATP hydrolysing) | |
| gdc.oaire.keywords | enzyme stability | |
| gdc.oaire.keywords | DNA topoisomerase | |
| gdc.oaire.keywords | gyrase inhibitor | |
| gdc.oaire.keywords | Enzyme Assays | |
| gdc.oaire.keywords | DNA strand breakage | |
| gdc.oaire.keywords | DNA topoisomerase inhibitor | |
| gdc.oaire.keywords | DNA Breaks | |
| gdc.oaire.keywords | article | |
| gdc.oaire.keywords | Gossypol | |
| gdc.oaire.keywords | enzyme activation | |
| gdc.oaire.keywords | gossypol | |
| gdc.oaire.keywords | Enzyme Activation | |
| gdc.oaire.keywords | DNA Topoisomerases, Type II | |
| gdc.oaire.keywords | DNA Topoisomerases, Type I | |
| gdc.oaire.keywords | Mammalia | |
| gdc.oaire.keywords | Gyrase inhibitor | |
| gdc.oaire.keywords | Topoisomerase I Inhibitors | |
| gdc.oaire.keywords | DNA Topoisomerases | |
| gdc.oaire.keywords | Plasmids | |
| gdc.oaire.popularity | 6.5662666E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 0301 basic medicine | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.oaire.sciencefields | 0303 health sciences | |
| gdc.oaire.views | 2 | |
| gdc.openalex.collaboration | National | |
| gdc.openalex.fwci | 0.56065978 | |
| gdc.openalex.normalizedpercentile | 0.65 | |
| gdc.opencitations.count | 11 | |
| gdc.plumx.crossrefcites | 7 | |
| gdc.plumx.mendeley | 17 | |
| gdc.plumx.pubmedcites | 4 | |
| gdc.plumx.scopuscites | 14 | |
| gdc.scopus.citedcount | 14 | |
| gdc.wos.citedcount | 12 | |
| relation.isAuthorOfPublication.latestForDiscovery | 7bb863bb-9384-4a07-9fbb-b9c1ab7634a3 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 9af2b05f-28ac-4013-8abe-a4dfe192da5e |
